Panorama
From On-Target to In-Play: Why Mass Marketing Methods Don’t Work for Pharma
Marketers in all verticals want to be on target. Sending the right message to ...
Is Step Therapy Now a Possibility for Part B Drugs?
The Trump administration’s drug cost blueprint looked at the possibility of moving Part B ...
Improving Drug Development with Innovation: Barriers & Enablers Impacting Adoption
In my last article, I discussed a new report, titled The Innovation Imperative: The ...
Speaker Bureau: Better Choices for Turbulent Times
A tactic with many names, “Speaker Bureau,” “Peer to Peer,” “Promotional Programs,” “Speaker Programs,” ...
Inside the Gray Space of Digital Therapeutics
I recently attended the second DTxDM conference of the year, which was held on ...
What Do Facebook Ad Changes Mean for Medical Advertising?
Facebook is currently weathering crises on multiple fronts. Investor confidence is declining, user patience ...
Changing Roles in Pharma & Biotech Companies: CSMs Are the New CRAs
The rapidly evolving clinical trial paradigm is prompting altered expectations of the traditional Clinical ...
It’s Programmatic, Not Program Magic, Advertising
Something Eugene Lee, Executive Vice President, Managing Director at CMI, said earlier this month ...
Crafting Highly Effective Incentive Compensation Plans for Your Sales Force
A fair and rewarding incentive compensation plan is an essential component of any successful ...
The Impact of Express Scripts’ 2019 Formulary Exclusion List
Earlier this month, Express Scripts announced its 2019 National Preferred Formulary (NPF), which added ...
What the “Healthcare Consumerism” Movement Means for Marketers
Between 2010 and 2014, the proportion of U.S. residents under the age of 65 ...
The Muscular Dystrophy Association Launches Expanded Patient Data Hub Initiative
The Muscular Dystrophy Association (MDA) has been building a longitudinal provider-entered registry of neuromuscular ...